Alto Neuroscience (ANRO) Change in Account Payables (2023 - 2026)
Alto Neuroscience (ANRO) reported Change in Account Payables of $1.5 million for Q1 2026, up 660.15% on a YoY basis from $196013.8 in Q1 2025, and up 601.68% sequentially from -$297000.0 in Q4 2025.
Alto Neuroscience (ANRO) Change in Account Payables (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Change in Account Payables data on file, last reported at $1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 660.15% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (up 327.24% YoY), and the FY2025 full-year result was $221000.0, down 57.17% from the prior year.
- Change in Account Payables improved to $1.5 million in Q1 2026, from -$297000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.5 million in Q1 2026 to a low of -$781000.0 in Q4 2023.
- A 4-year average of $122692.3 and a median of -$251000.0 in 2024 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables tumbled 123.75% in 2025 and jumped 660.15% in 2026, its largest moves.
- Tracing ANRO's Change in Account Payables over 4 years: stood at -$781000.0 in 2023, then gained by 2.43% to -$762000.0 in 2024, then surged by 61.02% to -$297000.0 in 2025, then soared by 601.68% to $1.5 million in 2026.
- Business Quant data shows ANRO's Change in Account Payables at $1.5 million in Q1 2026, -$297000.0 in Q4 2025, and $461000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - | 1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.49 Mn |
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | -297,000.00 |
| Dec 31, 2025 | -297,000.00 |
| Sep 30, 2025 | 461,000.00 |
| Sep 30, 2025 | 461,000.00 |
| Jun 30, 2025 | 323,000.00 |
| Jun 30, 2025 | 323,000.00 |
| Mar 31, 2025 | -266,000.00 |
| Mar 31, 2025 | -266,000.00 |
| Dec 31, 2024 | -762,000.00 |
| Dec 31, 2024 | -762,000.00 |
| Sep 30, 2024 | 409,000.00 |
| Sep 30, 2024 | 409,000.00 |
| Jun 30, 2024 | -251,000.00 |
| Jun 30, 2024 | -251,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | -781,000.00 |
| Dec 31, 2023 | -781,000.00 |